Pharma Wisdom provides job updates in the pharmaceutical, life science, and healthcare industries, facilitating recruitment efforts.

Pharma Wisdom

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Concord Biotech Limited

A pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products.

Dr. Reddy's

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Metric
Company Name	Pharma Wisdom	Concord Biotech Limited	Dr. Reddy's	Glenmark Pharmaceuticals Limited
Symbol		CONCORDBIO		GLENMARK
MSH ID	IN:CO:PHARMAWISDOM	COM:CONCORDBIOTECH	COM:DRREDDYS	COM:GLENMARKPHARMA
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Commercial & Professional Services	Healthcare	Healthcare & Health Services	Healthcare
Industry	Healthcare	Biotechnology	Pharmaceuticals	Drug Manufacturers - Specialty & Generic
Country	IN	IN	IN	IN
Stage
Employee Count		1.38K	26.27K	15.56K
Website	pharmawisdom.co.in	concordbiotech.com	drreddys.com	glenmarkpharma.com
LinkedIn		concord-biotech-limited	dr--reddys-laboratories
Founders

Metric
Market Cap	2.09B		4.61B
Enterprise Value
Monthly Web Traffic		142.34K
Web Traffic Growth		0.10
Valuation
Raised Capital

Metric
Revenue	120.06M	1.39B
Revenue (LTM)
Revenue (NTM)
Gross Profit	72.15M	466.30M
EBITDA	50.95M	141.12M
Operating Income	44.62M	72.42M
Net Income	36.38M	-177.29M
EPS	0.35	-0.63
Diluted EPS	0.35	-0.63
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.73	0.62
Operating Profit Margin	0.40	0.07
EBITDA Margin	0.42	0.10
Net Profit Margin	0.32	-0.06
Return on Equity	0.23	-0.07
Return on Assets	0.18
Return on Capital Employed	0.25	0.10

IN:CO:PHARMAWISDOM

Pharma Wisdom

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	51.37	-284.91
P/B Ratio	11.55	2.68
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	26.17	4.30
EV Multiple	59.58	36.82

Metric
Days Sales Outstanding		161.17
Days Payables Outstanding		146.28
Days Inventory Outstanding	238.56	172.88
Operating Cycle	364.05	229.31
Cash Conversion Cycle	255.71	55.48
Asset Turnover	0.61	0.84

Metric
Operating Cash Flow	31.57M	-90.32M
Free Cash Flow	21.46M	-198.34M
Cash Flow to Debt	21.88	0.83
Operating Cash Flow/Sales	0.22	0.07
Free Cash Flow Yield	0.01	0.00

Metric
Cash & Equivalents	5.55M	195.92M
Accounts Receivable	-9.29M	114.46M
Inventory	24.55M	296.69M
Goodwill		7.95M
Debt to Capitalization	0.01	0.14
Debt to Assets		0.26
Current Ratio		1.93
Quick Ratio	4.84	0.84

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.00
R&D to Revenue
SG&A to Revenue